LETYBO (letibotulinumtoxina-wlbg)
LETYBO (letibotulinumtoxinA-wlbg) is an acetylcholine release inhibitor and neuromuscular blocking agent. It is indicated for the temporary improvement in the appearance of moderate to severe glabellar lines in adult patients. The treatment specifically targets lines associated with the activity of the corrugator and/or procerus muscles. Its therapeutic role is to provide a temporary reduction in muscle activity in the localized area of injection.
How LETYBO Works
LETYBO blocks cholinergic transmission at the neuromuscular junction by inhibiting the release of the neurotransmitter acetylcholine. Once injected, the drug enters the nerve terminal and cleaves SNAP25, a protein necessary for the release of acetylcholine into the synapse. This process results in a dose-dependent decrease in muscle function. Muscle activity gradually returns as the neurotoxin degrades and the nerves form axonal sprouts to reinnervate the muscle.
Details
- Status
- Prescription
- First Approved
- 2024-02-29
- Routes
- N/A
- Dosage Forms
- POWDER, FOR SOLUTION
LETYBO Approval History
What LETYBO Treats
1 indicationsLETYBO is approved for 1 conditions since its original approval in 2024. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Glabellar Lines
LETYBO Boxed Warning
DISTANT SPREAD OF TOXIN EFFECT The effects of all botulinum toxin products, including LETYBO, may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. LETYBO is not approved for the treatment of spasticity or any conditions other than glabellar lines [see Warnings and Precautions ( 5.1 )] . ...
WARNING: DISTANT SPREAD OF TOXIN EFFECT The effects of all botulinum toxin products, including LETYBO, may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. LETYBO is not approved for the treatment of spasticity or any conditions other than glabellar lines [see Warnings and Precautions ( 5.1 )] . WARNING: DISTANT SPREAD OF TOXIN EFFECT See full prescribing information for complete boxed warning. The effects of all botulinum toxin products, including LETYBO, may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. LETYBO is not approved for the treatment of spasticity or any conditions other than glabellar lines. ( 5.1 )
LETYBO Competitive Set
ProThree rings of competition based on shared molecular targets and treated indications.
Direct competitors
Same target(s) AND same indication — head-to-head.
Indication competitors
Same indication, different mechanism — what else might this patient receive?
Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.
Drugs Similar to LETYBO
3 of 4FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
LETYBO FDA Label Details
Indications & Usage
FDA Label (PDF)LETYBO is indicated for the treatment of Glabellar Lines.
WARNING: DISTANT SPREAD OF TOXIN EFFECT The effects of all botulinum toxin products, including LETYBO, may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficu...
Track LETYBO with TheraRadar Pro
Watchlist alerts, full database access, CSV exports across 14,000+ drugs.
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.